Skip to main
STAA

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 13%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Staar Surgical is well-positioned for continued growth, with strong first quarter results, an increased price target, and potential for future growth in both China and the US. The company's dominant market position and proprietary Collamer material make it a potential leader in the industry. With a positive tone from management and expected increases in cash and investments, Staar Surgical is a strong investment opportunity.

Bears say

Staar Surgical is seeing strong performance in the US market driven by increased surgeon adoption and a focused marketing strategy, leading to share gains in a declining refractive surgery market. The recent FDA approval for expanded indications and underappreciated long-term growth potential make the US market a key driver for the company. The positive China revenue rebound, outperforming expectations and approaching normalized levels, is demand-driven and reflects the strong launch of EVO+ ICL. With management expecting to fully meet demand for EVO+ by end of 2Q'26, we see potential for solid full-year growth in ex-China revenue, driven by strong demand for EVO+ and management's confidence in the +MSD% to +10% range.

STAAR Surgical (STAA) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 8 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.